Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab

• Status: Unknown status
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: To evaluate the acute changes in intraocular cytokines after intravitreal bevacizumab (IVB) in proliferative diabetic retinopathy.

Design: Prospective, open-label, controlled, randomized interventional clinical trial.

Participants: Twenty eyes of 28 consecutive patients who are scheduled for pars plana vitrectomy (ppV) for proliferative diabetic retinopathy were prospectively enrolled.

Methods: All patients were randomly assigned to receive IVB either at 2 or 7 days before ppV. Aqueous humor samples were taken from anterior chamber just before IVB and at the time of surgery. Multiplex cytokine array were used to assay various cytokines

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul St. Mary's Hospital
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with proliferative diabetic retinopathy who were scheduled for PPV for vitreous hemorrhage or tractional retinal detachment (TRD)

Exclusion Criteria:

• Eyes with any pharmacologic intervention on study eye within 6 months

• Eyes with panretinal photocoagulation on study eye within 3 months

• Eyes with any pharmacologic intervention on fellow eye within 3 months,

• History of ocular diseases other than diabetic retinopathy

• History of PPV on study eye

• History of systemic thromboembolic events including myocardial infarction and cerebrovascular accidents.